Publications by authors named "Silvia Camera"

Claim this Profile
D
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers.
Margherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, Oluseyi Abidoye, Jessica Lucchetti, Silvia Camera

Liver Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.
Federica Lo Prinzi, Francesca Salani, Silvia Camera, Mario Domenico Rizzato, Anna Saborowski

Int J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Chiara Pirrone, Umberto Malapelle, Francesco Pepe, Federica Lo Prinzi, Federico Nichetti, Silvia Camera

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.
Federica Lo Prinzi, Federico Rossari, Antonio De Rosa, Caterina Vivaldi, Masatoshi Kudo, Silvia Camera

Hepatol Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population.
Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, Mario Domenico Rizzato, Anna Saborowski, Silvia Camera

J Natl Cancer Inst· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.
Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, Mario Domenico Rizzato, Anna Saborowski, Silvia Camera

Int J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study.
Monica Niger, Margherita Rimini, Florian Castet, Anna Melzer, Mario Domenico Rizzato, Silvia Camera

Liver Int· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution.
Margherita Rimini, Silvia Foti, Silvia Camera, Federico Rossari, Francesco Vitiello

Oncology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population.
Francesco Vitiello, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Silvia Camera

Semin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy.
Francesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, Anna Saborowski, Lorenzo Antonuzzo, Silvia Camera

Oncology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index.
Mara Persano, Margherita Rimini, Francesca Salani, Federica Lo Prinzi, Federico Nichetti, Silvia Camera

Liver Int· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting.
Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Camera, Silvia Foti

Target Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
Mara Persano, Andrea Casadei-Gardini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Silvia Camera

Oncology· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes.
Silvia Camera, Margherita Rimini, Silvia Foti, Federica Lo Prinzi, Francesco Vitiello

Oncology· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Federica Lo Prinzi, Francesca Salani, Margherita Rimini, Mario Domenico Rizzato, Lorenzo Antonuzzo, Silvia Camera

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions.
Silvia Camera, Federico Rossari, Silvia Foti, Francesco Vitiello, Mara Persano

Target Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Silvia Camera

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients.
Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Foti, Silvia Camera

Expert Rev Gastroenterol Hepatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.
Elisabeth Amadeo, Silvia Foti, Silvia Camera, Federico Rossari, Mara Persano

Expert Opin Investig Drugs· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab.
Margherita Rimini, Margarida Montes, Elisabeth Amadeo, Francesco Vitiello, Masatoshi Kudo, Silvia Camera

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Silvia Camera

Target Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment options for advanced hepatocellular carcinoma: the potential of biologics.
Federico Rossari, Silvia Foti, Silvia Camera, Mara Persano, Andrea Casadei-Gardini

Expert Opin Biol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Silvia Camera

Liver Int· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
Silvia Camera, Margherita Rimini, Federico Rossari, Toshifumi Tada, Goki Suda

Target Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does immunotherapy change the treatment paradigm in metastatic gastric cancer?
Silvia Camera, Nicole Liscia, Silvia Foti, Lavinia Barbieri, Andrea Cossu

Med Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis